170 related articles for article (PubMed ID: 24492295)
1. Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies.
Vugts DJ; Heuveling DA; Stigter-van Walsum M; Weigand S; Bergstrom M; van Dongen GA; Nayak TK
MAbs; 2014; 6(2):567-75. PubMed ID: 24492295
[TBL] [Abstract][Full Text] [Related]
2. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.
Menke-van der Houven van Oordt CW; Gomez-Roca C; van Herpen C; Coveler AL; Mahalingam D; Verheul HM; van der Graaf WT; Christen R; Rüttinger D; Weigand S; Cannarile MA; Heil F; Brewster M; Walz AC; Nayak TK; Guarin E; Meresse V; Le Tourneau C
Oncotarget; 2016 Nov; 7(48):80046-80058. PubMed ID: 27507056
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
[TBL] [Abstract][Full Text] [Related]
4. PET/CT Imaging of
Li W; Wang Y; Rubins D; Bennacef I; Holahan M; Haley H; Purcell M; Gantert L; Hseih S; Judo M; Seghezzi W; Zhang S; van der Veen EL; Lub-de Hooge MN; de Vries EGE; Evelhoch JL; Klimas M; Hostetler ED
Mol Imaging Biol; 2021 Apr; 23(2):250-259. PubMed ID: 33104972
[TBL] [Abstract][Full Text] [Related]
5.
Park JW; Jung KH; Lee JH; Moon SH; Cho YS; Lee KH
Sci Rep; 2021 Feb; 11(1):3876. PubMed ID: 33594192
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44.
Diebolder P; Mpoy C; Scott J; Huynh TT; Fields R; Spitzer D; Bandara N; Rogers BE
J Nucl Med; 2021 Jan; 62(1):137-143. PubMed ID: 32513906
[TBL] [Abstract][Full Text] [Related]
7. CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.
Birzele F; Voss E; Nopora A; Honold K; Heil F; Lohmann S; Verheul H; Le Tourneau C; Delord JP; van Herpen C; Mahalingam D; Coveler AL; Meresse V; Weigand S; Runza V; Cannarile M
Clin Cancer Res; 2015 Jun; 21(12):2753-62. PubMed ID: 25762343
[TBL] [Abstract][Full Text] [Related]
8.
Yang R; Lu M; Ming L; Chen Y; Cheng K; Zhou J; Jiang S; Lin Z; Chen D
Int J Nanomedicine; 2020; 15():9061-9074. PubMed ID: 33239874
[TBL] [Abstract][Full Text] [Related]
9. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
10. Zr-89 Immuno-PET Targeting Ectopic ATP Synthase Enables In-Vivo Imaging of Tumor Angiogenesis.
Park BN; Kim GH; Ko SA; Shin GH; Lee SJ; An YS; Yoon JK
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412537
[TBL] [Abstract][Full Text] [Related]
11. Preclinical PET imaging with the novel human antibody
Kelly MP; Makonnen S; Hickey C; Arnold TC; Giurleo JT; Tavaré R; Danton M; Granados C; Chatterjee I; Dudgeon D; Retter MW; Ma D; Olson WC; Thurston G; Kirshner JR
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483343
[TBL] [Abstract][Full Text] [Related]
12. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
[TBL] [Abstract][Full Text] [Related]
13. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
[TBL] [Abstract][Full Text] [Related]
14. Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody.
Jauw YWS; Huisman MC; Nayak TK; Vugts DJ; Christen R; Naegelen VM; Ruettinger D; Heil F; Lammertsma AA; Verheul HMW; Hoekstra OS; van Dongen GAMS; Menke-van der Houven van Oordt CW
EJNMMI Res; 2018 Jan; 8(1):6. PubMed ID: 29356983
[TBL] [Abstract][Full Text] [Related]
15. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
[TBL] [Abstract][Full Text] [Related]
16. Probody Therapeutic Design of
Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M
Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313
[TBL] [Abstract][Full Text] [Related]
17. Molecular imaging of T cell co-regulator factor B7-H3 with
Burvenich IJG; Parakh S; Lee FT; Guo N; Liu Z; Gan HK; Rigopoulos A; O'Keefe GJ; Gong SJ; Goh YW; Tochon-Danguy H; Scott FE; Kotsuma M; Hirotani K; Senaldi G; Scott AM
Theranostics; 2018; 8(15):4199-4209. PubMed ID: 30128047
[TBL] [Abstract][Full Text] [Related]
18. Tumor uptake and tumor/blood ratios for [
Al-Saden N; Cai Z; Reilly RM
Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for
Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258
[TBL] [Abstract][Full Text] [Related]
20. Total-Body PET and Highly Stable Chelators Together Enable Meaningful
Berg E; Gill H; Marik J; Ogasawara A; Williams S; van Dongen G; Vugts D; Cherry SR; Tarantal AF
J Nucl Med; 2020 Mar; 61(3):453-460. PubMed ID: 31562219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
